syntaxin


Also found in: Acronyms, Wikipedia.

syntaxin

(sin-taks'in),
A plasma membrane protein essential for synaptic vesicle fusion.
References in periodicals archive ?
There was first-degree consanguinity between the parents of 15 patients and the parents of 3 other patients were from the same village, suggesting possible consanguinity; therefore, the families were further analyzed via haplotype analysis for HLH mutations, including perforin, munc 13-4, and syntaxin 11 genes, and none had haplotype homozygosity for these genes.
BoNTs/B, D, F, and G cleave the vesicle-associated membrane protein and synaptobrevin, BoNT/A and E target the synaptosomal-associated protein SNAP-25, and BoNT/C hydrolyzes syntaxin and SNAP-25 (42,45,46).
The related neurotransmitter transporters GAT1, NET, and SERT interact with the SNARE protein syntaxin 1A, and this interaction plays a role in their subcellular localization and functional regulation.
Collaboration to leverage Syntaxin and Ipsen's expertise in the discovery and development of botulinum toxins
Syntaxin, IGFBP3, decorin, the bax inhibitor gene and the PEBP gene were assigned to BTA 3, 4, 5, 5, and 17, respectively.
Confocal and Immunoprecipitation studies also reveal the interaction of TRPC3 with VAMP2, aSNAR NSF and SYNTAXIN 3-proteins involved in vesicular trafficking.
one of the leading GMP contract manufacturers of biopharmaceuticals, announced today that it has signed an agreement with Syntaxin to produce its novel drug candidate SXN101959.
OXFORD, England, March 2, 2011 /PRNewswire/ -- Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announces its partner Allergan, Inc has initiated two Phase II trials to evaluate the safety and efficacy of its re-targeted endopeptidase drug candidate AGN-214868.
He has also served as non-executive chairman of Syntaxin, Novacta Biosystems, non-executive director of Synosia and was a venture partner with Abingworth LLP.
OXFORD, England, January 6, 2011 /PRNewswire/ -- Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announced Dr Russell G.